Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02060253 · ClinicalTrials.gov registry record · Phase 1
Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02060253: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02060253 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02060253, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of ganetespib when given with paclitaxel, trastuzumab and pertuzumab in treating patients with human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer (MBC).
Interventions
- DRUG paclitaxel
- BIOLOGICAL trastuzumab
- BIOLOGICAL pertuzumab
- DRUG ganetespib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2014-04 |
| Est. Completion | 2018-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02060253
The ClinicalTrials.gov registry entry for NCT02060253 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which paclitaxel is the first listed.
NCT02060253 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02060253 about?
NCT02060253 is a clinical study titled "Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer". This phase I trial studies the side effects and best dose of ganetespib when given with paclitaxel, trastuzumab and pertuzumab in treating patients with human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer (MBC).
What is the current status of trial NCT02060253?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2014-04. Estimated completion is 2018-06.
What interventions are being tested in trial NCT02060253?
The interventions under investigation include: paclitaxel (DRUG), trastuzumab (BIOLOGICAL), pertuzumab (BIOLOGICAL), ganetespib (DRUG).
Who is sponsoring clinical trial NCT02060253?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.